Part,  Chapter, Paragraph

 1   II,     5. 15.Acr|             COMP~Committee of Orphan Medicinal Products~EMEA~European Medicines
 2   II,     5. 15.  3|         Currently over 40 new orphan medicinal products are on the EU market
 3   II,     5. 15.  3|              legal delay for placing medicinal products on the market is
 4   II,     5. 15.  4|              December 1999 on orphan medicinal products sets up the criteria
 5   II,     5. 15.  4|             the concepts of "similar medicinal product" and "clinical superiority".
 6   II,     5. 15.  4|     Regulation No 141/2000 on Orphan Medicinal Products in the first five
 7   II,     5. 15.  4|          Council on advanced therapy medicinal products (European Commission,
 8   II,     5. 15.  4|            the development of Orphan Medicinal Products and adapt their
 9   II,     5. 15.  4|               a Committee for Orphan Medicinal Products (COMP) was established
10   II,     5. 15.  4|            the designation of orphan medicinal products, and for advising
11   II,     5. 15.  6|          developing and using orphan medicinal products. Br J Clin Pharmacol
12   II,     5. 15.  6|           and Availability of Orphan Medicinal Products, Revision 2005.
13   II,     5. 15.  6|             2007 on advanced therapy medicinal products and amending Directive
14   II,     6.  4.  5|           may occur not only through medicinal products but also through:~ ~·
15   II,     7.  4.  6|     dialectical therapy and specific medicinal products.~ ~As suicide is
16   II,     9.  1.  2|              systematic follow-up of medicinal drugs and assisted reproduction
17   II,     9.  2.  5|        Parliament and the Council on medicinal products for paediatric
18   II,     9.  2.  5|            and the paediatric use of medicinal products.~ ~In addition,
19  III,    10.  2.  1|              and are either based on medicinal nicotine (NRT) use or on
20  III,    10.  4.  2|               residues of veterinary medicinal products to prevent or treat
21  III,    10.  4.  2|            on residues of veterinary medicinal products used in food-producing
22   IV,    11.  6.  5|            10-18.~ ~Illich I (1975): Medicinal nemesis. New York: Pantheon~ ~
23   IV,    12.  1    |             the protection of orphan medicinal products~Information~Society~
24   IV,    12. 10    |              is working on safety of medicinal products and risk monitoring
25   IV,    12. 10    |              regards investigational medicinal products for human use,
26   IV,    12. 10    |           Community code relating to medicinal products for human use as
27   IV,    12. 10    | manufacturing practice in respect of medicinal products for human use and
28   IV,    12. 10    |              use and investigational medicinal products for human use (
29   IV,    13.  7    |         producing, among others, new medicinal products, medical devices,
30   IV,    13.  7    |     manufactured into plasma-derived medicinal products. The therapeutic